Brokerages Set Context Therapeutics Inc. (NASDAQ:CNTX) Price Target at $6.00

Context Therapeutics Inc. (NASDAQ:CNTX) has been given a consensus rating of “Buy” by the six research firms that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $5.50.

A number of equities analysts have commented on CNTX shares. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Context Therapeutics in a research note on Friday, March 21st. Piper Sandler reaffirmed an “overweight” rating and set a $4.00 price target (down previously from $4.50) on shares of Context Therapeutics in a research note on Thursday. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a research note on Thursday, May 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Context Therapeutics in a research note on Tuesday, April 29th.

Insiders Place Their Bets

In other news, CFO Jennifer Lynn Minai-Azary acquired 40,010 shares of Context Therapeutics stock in a transaction dated Friday, June 6th. The stock was bought at an average cost of $0.64 per share, with a total value of $25,606.40. Following the completion of the transaction, the chief financial officer now directly owns 80,010 shares of the company’s stock, valued at approximately $51,206.40. This represents a 100.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martin A. Lehr acquired 100,000 shares of Context Therapeutics stock in a transaction dated Monday, June 9th. The shares were purchased at an average cost of $0.70 per share, with a total value of $70,000.00. Following the completion of the transaction, the chief executive officer now directly owns 920,190 shares of the company’s stock, valued at $644,133. This trade represents a 12.19% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 160,010 shares of company stock worth $107,206 over the last ninety days. 2.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. MPM Bioimpact LLC bought a new position in shares of Context Therapeutics during the fourth quarter worth approximately $15,441,000. Blue Owl Capital Holdings LP increased its stake in shares of Context Therapeutics by 17.5% during the fourth quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company’s stock worth $6,676,000 after purchasing an additional 946,638 shares during the period. Franklin Resources Inc. increased its stake in Context Therapeutics by 115.9% during the 4th quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company’s stock worth $4,204,000 after acquiring an additional 2,149,392 shares during the period. Allostery Investments LP bought a new position in Context Therapeutics during the 4th quarter worth $998,000. Finally, Geode Capital Management LLC increased its stake in Context Therapeutics by 9.2% during the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock worth $661,000 after acquiring an additional 52,830 shares during the period. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Price Performance

Shares of Context Therapeutics stock opened at $0.66 on Thursday. The stock has a 50-day simple moving average of $0.72 and a 200-day simple moving average of $0.83. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $2.75. The firm has a market cap of $59.22 million, a price-to-earnings ratio of -2.13 and a beta of 1.86.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). As a group, equities research analysts predict that Context Therapeutics will post -0.51 earnings per share for the current year.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.